Abstract

Purpose: To evaluate clinical and tumor characteristics in patients receiving high-dose chemotherapy and autologous peripheral stem-cell transplantation (PSCT) or bone marrow transplantation (ABMT) for relapsed or primary refractory non-Hodgkin's lymphoma (NHL). Patients and Methods: One hundred fifty-eight patients with NHL received high-dose chemotherapy and ABMT or PSCT. A multivariate analysis of characteristics was performed for comparison of the long-term failure-free survival (FFS) rate. Results: Using a multivariate analysis, a prognostic model was constructed with patients in the good-prognosis group being those without a mass ≥ 10 cm at the time of transplant, and no more than one of the following characteristics: three or more prior chemotherapy regimens, lactate dehydrogenase (LDH) level above normal, and chemotherapy resistance. Patients in the poor-prognosis group had a mass ≥ 10 cm, or two of the other characteristics noted. The poor-prognosis group had a 3-year FFS rate of 10%, compared with a 45% 3-year FFS in the good-prognosis group (P < .001). Within the prognostic groups, there was no difference in the 3-year FFS rate of the poor-prognosis patients who received ABMT versus PSCT (10% v 12%; not significant). However, in the good-prognosis group, patients who received ABMT had a 3-year FFS rate of 32%, compared with 70% for those who received PSCT (P < .008). Conclusion: This prognostic model can identify patients with good and poor prognoses following high-dose chemotherapy and ABMT or PSCT for aggressive NHL. In good-prognosis patients, those who received PSCT had a superior FFS rate.

Original languageEnglish (US)
Pages (from-to)1846-1851
Number of pages6
JournalJournal of Clinical Oncology
Volume11
Issue number10
DOIs
StatePublished - Jan 1 1993

Fingerprint

Hematopoietic Stem Cell Transplantation
Non-Hodgkin's Lymphoma
Peripheral Blood Stem Cell Transplantation
Drug Therapy
Survival Rate
Multivariate Analysis
Bone Marrow Transplantation
L-Lactate Dehydrogenase
Transplants
Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{814fe749e08b4ee58e9b498038ab7d31,
title = "High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma",
abstract = "Purpose: To evaluate clinical and tumor characteristics in patients receiving high-dose chemotherapy and autologous peripheral stem-cell transplantation (PSCT) or bone marrow transplantation (ABMT) for relapsed or primary refractory non-Hodgkin's lymphoma (NHL). Patients and Methods: One hundred fifty-eight patients with NHL received high-dose chemotherapy and ABMT or PSCT. A multivariate analysis of characteristics was performed for comparison of the long-term failure-free survival (FFS) rate. Results: Using a multivariate analysis, a prognostic model was constructed with patients in the good-prognosis group being those without a mass ≥ 10 cm at the time of transplant, and no more than one of the following characteristics: three or more prior chemotherapy regimens, lactate dehydrogenase (LDH) level above normal, and chemotherapy resistance. Patients in the poor-prognosis group had a mass ≥ 10 cm, or two of the other characteristics noted. The poor-prognosis group had a 3-year FFS rate of 10{\%}, compared with a 45{\%} 3-year FFS in the good-prognosis group (P < .001). Within the prognostic groups, there was no difference in the 3-year FFS rate of the poor-prognosis patients who received ABMT versus PSCT (10{\%} v 12{\%}; not significant). However, in the good-prognosis group, patients who received ABMT had a 3-year FFS rate of 32{\%}, compared with 70{\%} for those who received PSCT (P < .008). Conclusion: This prognostic model can identify patients with good and poor prognoses following high-dose chemotherapy and ABMT or PSCT for aggressive NHL. In good-prognosis patients, those who received PSCT had a superior FFS rate.",
author = "Vose, {Julie Marie} and Anderson, {James R.} and Anne Kessinger and Bierman, {Philip Jay} and Peter Coccia and Reed, {Elizabeth Cecile} and Gordon, {Bruce Geoffrey} and Armitage, {James Olen}",
year = "1993",
month = "1",
day = "1",
doi = "10.1200/JCO.1993.11.10.1846",
language = "English (US)",
volume = "11",
pages = "1846--1851",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma

AU - Vose, Julie Marie

AU - Anderson, James R.

AU - Kessinger, Anne

AU - Bierman, Philip Jay

AU - Coccia, Peter

AU - Reed, Elizabeth Cecile

AU - Gordon, Bruce Geoffrey

AU - Armitage, James Olen

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Purpose: To evaluate clinical and tumor characteristics in patients receiving high-dose chemotherapy and autologous peripheral stem-cell transplantation (PSCT) or bone marrow transplantation (ABMT) for relapsed or primary refractory non-Hodgkin's lymphoma (NHL). Patients and Methods: One hundred fifty-eight patients with NHL received high-dose chemotherapy and ABMT or PSCT. A multivariate analysis of characteristics was performed for comparison of the long-term failure-free survival (FFS) rate. Results: Using a multivariate analysis, a prognostic model was constructed with patients in the good-prognosis group being those without a mass ≥ 10 cm at the time of transplant, and no more than one of the following characteristics: three or more prior chemotherapy regimens, lactate dehydrogenase (LDH) level above normal, and chemotherapy resistance. Patients in the poor-prognosis group had a mass ≥ 10 cm, or two of the other characteristics noted. The poor-prognosis group had a 3-year FFS rate of 10%, compared with a 45% 3-year FFS in the good-prognosis group (P < .001). Within the prognostic groups, there was no difference in the 3-year FFS rate of the poor-prognosis patients who received ABMT versus PSCT (10% v 12%; not significant). However, in the good-prognosis group, patients who received ABMT had a 3-year FFS rate of 32%, compared with 70% for those who received PSCT (P < .008). Conclusion: This prognostic model can identify patients with good and poor prognoses following high-dose chemotherapy and ABMT or PSCT for aggressive NHL. In good-prognosis patients, those who received PSCT had a superior FFS rate.

AB - Purpose: To evaluate clinical and tumor characteristics in patients receiving high-dose chemotherapy and autologous peripheral stem-cell transplantation (PSCT) or bone marrow transplantation (ABMT) for relapsed or primary refractory non-Hodgkin's lymphoma (NHL). Patients and Methods: One hundred fifty-eight patients with NHL received high-dose chemotherapy and ABMT or PSCT. A multivariate analysis of characteristics was performed for comparison of the long-term failure-free survival (FFS) rate. Results: Using a multivariate analysis, a prognostic model was constructed with patients in the good-prognosis group being those without a mass ≥ 10 cm at the time of transplant, and no more than one of the following characteristics: three or more prior chemotherapy regimens, lactate dehydrogenase (LDH) level above normal, and chemotherapy resistance. Patients in the poor-prognosis group had a mass ≥ 10 cm, or two of the other characteristics noted. The poor-prognosis group had a 3-year FFS rate of 10%, compared with a 45% 3-year FFS in the good-prognosis group (P < .001). Within the prognostic groups, there was no difference in the 3-year FFS rate of the poor-prognosis patients who received ABMT versus PSCT (10% v 12%; not significant). However, in the good-prognosis group, patients who received ABMT had a 3-year FFS rate of 32%, compared with 70% for those who received PSCT (P < .008). Conclusion: This prognostic model can identify patients with good and poor prognoses following high-dose chemotherapy and ABMT or PSCT for aggressive NHL. In good-prognosis patients, those who received PSCT had a superior FFS rate.

UR - http://www.scopus.com/inward/record.url?scp=0027448798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027448798&partnerID=8YFLogxK

U2 - 10.1200/JCO.1993.11.10.1846

DO - 10.1200/JCO.1993.11.10.1846

M3 - Article

C2 - 8105034

AN - SCOPUS:0027448798

VL - 11

SP - 1846

EP - 1851

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -